Business
Immunic to Participate in Investor and Scientific Conferences in February
NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small
About this update from Immunic, Inc.
[{"type":"text","content":"NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February:\nFebruary 10-11: BIO CEO & Investor Conference 2025. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in one-on-one meetings at this conference, taking place in New York. Interested parties can request a meeting through the BIO Partnering™ system or contact Jessica Breu at: [email protected] 11-12: Oppenheimer 35th Annual Healthcare Life Sciences Conference. Dr. Vitt will participate in a fireside chat at this virtual conference on Wednesday, February 12 at 1:20 pm ET. A webcast will be available on the \"Events and Presentations\" section of Immunic's website at: https://ir.imux.com/events-and-presentations.Additional team members, including Jason Tardio, President and Chief Operating Officer, Glenn Whaley, Chief Financial Officer, and Jessica Breu, Vice President Investor Relations and Communications, will also be in attendance to participate in one-on-one meetings at the conference. To schedule a meeting, please contact your Oppenheimer representative or Jessica Breu at: [email protected] 19-22: 19th Congress of ECCO (European Crohn's and Colitis Organisation). Members of Immunic's medical, clinical and preclinical teams will attend this congress in Berlin, Germany, where two abstracts discussing clinical and preclinical data on IMU-856, Immunic's orally available and systemically acting small molecule modulator that targets Sirtuin 6 (SIRT6), will be presented as digital oral presentations. The presentations will be accessible on the \"Events and Presentations\" section of Immunic's website at: https://ir.imux.com/events-and-presentations.Presentation Title: Promising Effects of IMU-856, an Orally Available Epigenetic Modulator of Barrier Regeneration - Biomarker Findings from a Phase 1 Clinical StudyPresenting Author: Amelie Schreieck, Ph.D., Senior Manager Biomarker Development, ImmunicAbstract Number: EC25-1515Presentation Number: DOP012Presentation Time: 5:57 pm – 6:03 pm CETSession Name: Digital Oral Presentation (DOP) Session 2: Clinical Trials IISession Da...